MACK

Merrimack Pharmaceuticals, Inc. (MACK) | Rumor.io

Merrimack Pharmaceuticals

MACK

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MACK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jan 17

The author is bullish on $MACK and plans to buy more, considering it a potential generational wealth opportunity.
The technical indicators for $MACK suggest a potential big move, with the bollinger bands getting super tight and the RSI and MACD indicating bearish momentum.
Partnerships and upgrades are key drivers for $MACK, and the author suggests keeping a close eye on the company's official channels for any news or updates.

Generated by AI

Sentiment

Of the messages about MACK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	71.36% -15.41
Bearish	—	—	—	28.64% +15.41

Bullish· Feb 13

$MACK is set to receive a $225M milestone payment from Ispen, a significant boost for the company.
The FDA approval of Onivyde, Merrimack Pharmaceuticals' cancer drug, is expected to drive the stock price higher, with potential targets ranging from $15.70 to $16.20.
The company's first FDA-approved cancer drug for pancreatic cancer has the potential to send the stock price higher, with a golden cross formation indicating increased momentum.

Bearish· Nov 17

The FDA's approval process for $MACK's drug may be slowed down due to current congressional investigations.
$MACK's stock price may drop by 50% due to the expiration of calls and the sale of puts.
The company's financial situation may be precarious, with some investors suggesting that it may go bankrupt before its drug is approved.

Generated by AI

Topics

Of the messages about MACK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	100%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Earnings· Nov 9

$MACK earnings report shows a net loss of $30.1 million for Q3 2016, compared to $50.8 million in Q2 2016.
$MACK's aggregate R&D and SG&A expenses decreased to $50.1 million in Q3 2016, compared to $61.7 million in Q2 2016.
$MACK reports FQ3 earnings of -$0.23 EPS and $28.07M Revs, beating the EPS consensus by 6c but missing the revenue consensus by $0.96M.

Announcements· Feb 13

The FDA has approved Onivyde (irinotecan liposome injection) + 5 fluorouracil/leucovorin and oxaliplatin as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
This approval triggers a $225M milestone payment from Ipsen to Merrimack Pharmaceuticals, Inc. (MACK).
Merrimack Pharmaceuticals will dissolve and distribute cash to shareholders, including a $225M payout tied to Onivyde's label expansion.

Technical Analysis· Nov 10

$MACK has shown a 1-month RSI of 89.19, indicating potential overbought conditions and a possible decline in price.
The stock has a low volume pump bull trap setup, with a limited number of shares and potential hedge liquidation, which may lead to a drop in price.
$MACK has broken out of consolidation and is expected to reach $12.60-$13.25, but may drop due to potential offering or profit taking, with key levels at 11.52 support and 12.90 resistance.

Generated by AI

Community

Of the messages about MACK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	76.71%
Newcomers	100%	100%	100%	23.29%

Regulars· Nov 9

Merrimack Pharmaceuticals ($MACK) has demonstrated value creation despite having zero employees since 2019, relying on consultant agreements, and could be a model for other negative EV companies.
The success of Merrimack's Onivyde regimen in a Phase 3 trial has led to a significant increase in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma, with Ipsen announcing the results.
Merrimack's stock has surged over 220% this year, making it a hot stock, but it's on the bearish side of its current trend, and a possible pullback to $11.50 may occur before its next main bounce.

Newcomers· Jan 17

Many newcomers are focusing on buying more of $MACK, with some even considering it a potential "generational wealth zone" due to its bullish outlook.
The current technical indicators for $MACK, such as the Bollinger Bands and RSI, are being closely watched by some users, who are anticipating a potential big move in the stock.
Users are also discussing potential catalysts for $MACK's next directional move, including partnerships, upgrades, and broader market factors, with some users cautioning that a period of observation may be prudent.

Generated by AI

Also Discussed

Investors talking about MACK also mention

#	Name	Attention
1	BDSI - BioDelivery Sciences International, Inc.	——
2	Halozyme Therapeutics Inc.HALO	0%0
3	Acadia Pharmaceuticals Inc.ACAD	0%+0
4	iShares Biotechnology ETFIBB	0.01%0
5	FOLD - Amicus Therapeutics, Inc.	——
6	Ironwood Pharmaceuticals, Inc. Class A Common StockIRWD	0%new
7	Exelixis Inc.EXEL	0%-0.03
8	Celldex Therapeutics IncCLDX	0%+0
9	XOMA CorporationXOMA	0%0
10	ALIM - Alimera Sciences, Inc.	——